This announcement is a separate document:
復宏漢霖：自願公告 - 帕妥珠單抗生物類似藥HLX11（重組抗HER2結構域II人源化單克隆抗體注射液）的上市註冊申請(NDA)獲國家藥品監督管理局(NMPA)受理
HENLIUS: VOLUNTARY ANNOUNCEMENT - NEW DRUG APPLICATION (NDA) FOR PERTUZUMAB BIOSIMILARHLX11 (RECOMBINANT ANTI-HER2 DOMAIN II HUMANIZEDMONOCLONAL ANTIBODY INJECTION) HAS BEEN ACCEPTED BY THENATIONAL MEDICAL PRODUCTS ADMINISTRATION (NMPA)
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.